Panamesine
http://dbpedia.org/resource/Panamesine an entity of type: Thing
Panamesine (INN; developmental code name EMD-57455) is a sigma receptor antagonist that was under development by Merck as a potential antipsychotic for the treatment of schizophrenia in the 1990s but was never marketed. It is a selective antagonist of both sigma receptor subtypes, the σ1 and σ2 receptors (IC50 = 6 nM). In addition, the major metabolite of the drug, , has high affinity for the sigma receptors (IC50 = 24 nM) and the dopamine D2 (IC50 = 23 nM) and D3 receptors, with potent antidopaminergic activity. Panamesine reached phase II clinical trials for schizophrenia prior to the discontinuation of its development.
rdf:langString
rdf:langString
Panamesine
xsd:integer
55035238
xsd:integer
1014748399
xsd:integer
23
xsd:integer
139225
xsd:integer
45686
xsd:integer
26
xsd:integer
-5
xsd:integer
2
xsd:integer
6
xsd:integer
3047810
rdf:langString
COC1=CC=CN2C[C@@H]CN3CCCO
xsd:integer
1
rdf:langString
NINYZUDVKTUKIA-IBGZPJMESA-N
rdf:langString
EMD-57455
xsd:integer
23
rdf:langString
Panamesine (INN; developmental code name EMD-57455) is a sigma receptor antagonist that was under development by Merck as a potential antipsychotic for the treatment of schizophrenia in the 1990s but was never marketed. It is a selective antagonist of both sigma receptor subtypes, the σ1 and σ2 receptors (IC50 = 6 nM). In addition, the major metabolite of the drug, , has high affinity for the sigma receptors (IC50 = 24 nM) and the dopamine D2 (IC50 = 23 nM) and D3 receptors, with potent antidopaminergic activity. Panamesine reached phase II clinical trials for schizophrenia prior to the discontinuation of its development.
xsd:nonNegativeInteger
4734
xsd:string
139225-22-2
xsd:string
45686
xsd:string
023D9E916L
xsd:string
3047810